The scheme is designed by UK government and delivered by the British Business Bank. The UK Future Fund, launched in April 2020, issues convertible loans to private UK companies with good potential that typically rely on equity investment and are currently affected by COVID-19. We believe Rinri’s’ technology is differentiated from other approaches to hearing loss restoration and has the potential to make a significant impact on treatment.” Our major investors share the vision we have for our technology to bring transformational changes to the lives of patients suffering from hearing loss, and the proceeds from this fund raising will allow us to advance our pioneering journey towards first in man clinical trials and to ultimately realise the potential of stem cell therapy to reverse sensorineural hearing loss.”įrank Kalkbrenner, Global Head of the Boehringer Ingelheim Venture Fund, added “We are delighted to continue our backing of Rinri and its pioneering approach to hearing loss, now with the added endorsement and support of the Future Fund. There are currently no pharmacological treatments available for SNHL despite the increasing number of patients that suffer from this condition globally.ĭr Simon Chandler, CEO of Rinri Therapeutics, commented: “We are very pleased to receive continuing support from existing investors alongside matched funding from the UK Future Fund. SNHL happens when there is damage to the hair cells in the cochlear and/or the auditory nerve. Objective: This article aims to review the current literature about the main types of stem cells with potential for application in cell therapy for sensorineural hearing loss, the most relevant experiments already performed in animals, as well as the advances that have been. Regenerative therapies using stem cells represent a promising alternative. However, there is no treatment that re-establishes auditory function. Rinri’s underlying technology, based on innovative research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield from where the company was spun out, seeks to reverse SNHL through the repair of the damaged cytoarchitecture in the inner ear. Hence, damage to these cell types is permanent and leads to hearing loss. Gene therapy is the future, but we don’t know when. The processed stem cells are injected into the specific area of. Fan-Gang Zeng, PhD, the director of the Center of Hearing Research at the University of California-Irvine School of Medicine, explained that gene therapy addresses hearing loss biologically by repairing or restoring damaged cells, which hearing aids or cochlear implants do not accomplish. After collection, the cells are processed according to the purpose for which they are extracted. The cells are collected from different body parts depending upon the need. The proceeds will support the development of the Company’s novel stem cell therapy to reverse sensorineural hearing loss (SNHL). The procedure of stem cell therapy starts with removing stem cells from your body or from the donor’s body. We review the potential applications of hiPSCs in the various biological approaches, including disease modeling, bioengineering, drug testing, and autologous stem cell based-cell therapy, that offer opportunities to understand the pathogenic mechanisms of SNHL and identify novel therapeutic strategies.Sheffield, UK, 20 April 2021: Rinri Therapeutics, a biotechnology company developing a novel stem cell therapy to restore hearing, today announces that it has raised a total of £10 million from existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund. Human induced pluripotent stem cells (hiPSCs) can be induced in two-dimensional and three-dimensional otic cells in vitro models that can generate inner ear progenitors and sensory HCs and could be a promising preclinical platform from which to work toward restoring SNHL. A major bottleneck for development of new therapies for SNHL is associated to the lack of human otic cell bioassays. To date, treatment options are limited to hearing aids and cochlear implants. SNHL is a major global health problem affecting millions of people worldwide and provides a growing concern in the aging population. This results in irreversible sensorineural hearing loss (SNHL) as in mammals, including humans the inner ear lacks the capacity to regenerate HCs and spiral ganglion neurons. Noise trauma, infections, genetic factors, side effects of ototoxic drugs (ie, some antibiotics and chemotherapeutics), or simply aging lead to the loss of HCs and their associated primary neurons. The success in differentiating stem cells into inner ear cell types raised the. The sense of hearing depends on a specialized sensory organ in the inner ear, called the cochlea, which contains the auditory hair cells (HCs). Genetic and acquired hearing loss affects 1 in 5 people translating to.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |